Kiromic BioPharma Statistics
Total Valuation
Kiromic BioPharma has a market cap or net worth of 1.39 million. The enterprise value is 13.18 million.
| Market Cap | 1.39M |
| Enterprise Value | 13.18M |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kiromic BioPharma has 1.55 million shares outstanding. The number of shares has increased by 49.37% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.55M |
| Shares Change (YoY) | +49.37% |
| Shares Change (QoQ) | +2.65% |
| Owned by Insiders (%) | 27.09% |
| Owned by Institutions (%) | n/a |
| Float | 1.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.43 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.61 |
Financial Position
The company has a current ratio of 0.22
| Current Ratio | 0.22 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.68 |
| Interest Coverage | -6.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -119.42% |
| Return on Capital (ROIC) | -237.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -873,757 |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.08% in the last 52 weeks. The beta is 1.96, so Kiromic BioPharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +73.08% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 44.10 |
| Average Volume (20 Days) | 1,352 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.39M |
| Pretax Income | -25.10M |
| Net Income | -30.58M |
| EBITDA | -21.17M |
| EBIT | -23.39M |
| Earnings Per Share (EPS) | -21.97 |
Balance Sheet
The company has 2.92 million in cash and 14.71 million in debt, giving a net cash position of -11.79 million or -7.63 per share.
| Cash & Cash Equivalents | 2.92M |
| Total Debt | 14.71M |
| Net Cash | -11.79M |
| Net Cash Per Share | -7.63 |
| Equity (Book Value) | -9.29M |
| Book Value Per Share | -6.01 |
| Working Capital | -14.83M |
Cash Flow
In the last 12 months, operating cash flow was -21.22 million and capital expenditures -446,600, giving a free cash flow of -21.67 million.
| Operating Cash Flow | -21.22M |
| Capital Expenditures | -446,600 |
| Free Cash Flow | -21.67M |
| FCF Per Share | -14.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kiromic BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.37% |
| Shareholder Yield | -49.37% |
| Earnings Yield | -2,440.92% |
| FCF Yield | -1,557.21% |
Stock Splits
The last stock split was on March 13, 2023. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Mar 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |